OBJECTIVE: The aim of this study was to validate the Korean version of the Brief Pain Inventory (BPI-K), a pain assessment tool that has been validated in several languages. METHODS: The sample consisted of 132 patients in Seoul who had recurrent or metastatic cancer and who expressed pain. The Korean version of the Beck Depression Inventory (BDI-K), the Eastern Cooperative Oncology Group (ECOG) performance status score, the Pain Management Index (PMI), and the PMI-Revised (PMI-R) were used to further validate the BPI-K. RESULTS: Cronbach alphas, computed for the pain interference and pain severity item, were 0.93 and 0.85, respectively. Confirmatory factor analysis of the BPI-K items showed a two-common-factor solution for the BPI-K, consistently demonstrated in other language versions of the BPI. The mean pain interference score was more correlated with the BDI-K scale (r = 0.44) and ECOG (r = 0.39) than the mean pain severity score. Seventy-four percent of the patients in the Seoul sample had inadequate analgesia using the PMI. CONCLUSION: The BPI-K is a valid and useful instrument for assessing cancer pain and pain impact in Korea. Copyright 2004 S. Karger AG, Basel
OBJECTIVE: The aim of this study was to validate the Korean version of the Brief Pain Inventory (BPI-K), a pain assessment tool that has been validated in several languages. METHODS: The sample consisted of 132 patients in Seoul who had recurrent or metastatic cancer and who expressed pain. The Korean version of the Beck Depression Inventory (BDI-K), the Eastern Cooperative Oncology Group (ECOG) performance status score, the Pain Management Index (PMI), and the PMI-Revised (PMI-R) were used to further validate the BPI-K. RESULTS: Cronbach alphas, computed for the pain interference and pain severity item, were 0.93 and 0.85, respectively. Confirmatory factor analysis of the BPI-K items showed a two-common-factor solution for the BPI-K, consistently demonstrated in other language versions of the BPI. The mean pain interference score was more correlated with the BDI-K scale (r = 0.44) and ECOG (r = 0.39) than the mean pain severity score. Seventy-four percent of the patients in the Seoul sample had inadequate analgesia using the PMI. CONCLUSION: The BPI-K is a valid and useful instrument for assessing cancer pain and pain impact in Korea. Copyright 2004 S. Karger AG, Basel
Authors: Thomas M Atkinson; Tito R Mendoza; Laura Sit; Steven Passik; Howard I Scher; Charles Cleeland; Ethan Basch Journal: Pain Med Date: 2010-01-15 Impact factor: 3.750
Authors: Jin Young Choi; Dong Wook Shin; Jina Kang; Young Ji Baek; Ha Na Mo; Byung-Ho Nam; Won Seok Seo; Jong Hyock Park; Jung Hoe Kim; Kee Taig Jung Journal: Support Care Cancer Date: 2011-02-24 Impact factor: 3.603
Authors: Barry J A Laird; John Walley; Gordon D Murray; Eleanor Clausen; Lesley A Colvin; Marie T Fallon Journal: Support Care Cancer Date: 2010-08-01 Impact factor: 3.603
Authors: Sang Min Park; Myung Hee Park; Joo Hee Won; Kyoung Ok Lee; Wha Sook Choe; Dae Seog Heo; Si-Young Kim; Kyung Sik Lee; Young Ho Yun Journal: Support Care Cancer Date: 2005-11-04 Impact factor: 3.603
Authors: Jung Hye Kwon; Sung Yong Oh; Gary Chisholm; Jung-Ae Lee; Jae Jin Lee; Keon Woo Park; Seung-Hyun Nam; Hun Ho Song; Keehyun Lee; Dae Young Zang; Ho Young Kim; Dae Ro Choi; Hyo Jung Kim; Jung Han Kim; Joo Young Jung; Geundoo Jang; Hyeong Su Kim; Ji Yun Won; Eduardo Bruera Journal: Support Care Cancer Date: 2012-11-15 Impact factor: 3.603